Biologics in Asthma

IF 2.7 3区医学 Q2 ALLERGY

Immunology and Allergy Clinics of North America Pub Date : 2024-08-22 DOI:10.1016/j.iac.2024.07.008

引用次数: 0

哮喘中的生物制剂：新兴生物制剂。

随着我们对哮喘病理生理学认识的不断深入，生物制剂等多种哮喘靶向疗法应运而生。然而，一些患者对生物制剂产生部分反应，表明疾病仍有活动性。因此，我们需要针对新途径的新疗法，或许还需要对生物制剂联合疗法和下游细胞因子激活调节剂进行评估。因此，尽管我们目前的重点是生物制剂，但关键是要采取一种更全面的方法，包括考虑非生物制剂疗法，这些疗法有可能极大地促进哮喘治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology and Allergy Clinics of North America 医学-过敏

CiteScore

5.40

自引率

3.80%

发文量

审稿时长

>12 weeks

期刊介绍： Immunology and Allergy Clinics of North America updates you on the latest trends in patient management; keeps you up to date on the newest advances; and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in immunology and allergy and is presented under the direction of an experienced guest editor. Topics include allergens, immunotherapy, anaphylaxis, asthma, drug allergy, eosinophilrelated disorders, food allergy, immunodeficiency states (non-HIV), basic science, mast cell disorders, rhinitis and sinusitis, and urticaria and angioedema. Immunology and Allergy Clinics of North America is published four times each year, in February, May, August, and November.